You are here: Industry Insights > DCVAC

News List

SOTIO Presents Positive Biomarker Data from DCVAC/OvCa Phase 2 Study in First Line Ovarian Cancer at the 2021 ASCO Annual Meeting b3cnewswire
June 07, 2021
SOTIO today announced the presentation of positive biomarker data from its Phase 2 trial with dendritic cell vaccine DCVAC/OvCa during a virtual poster presentation at the 2021 ASCO Annual Meeting.
Phase II Clinical Trials of DCVAC Show Significant Benefit for Patients with Ovarian and Lung Cancer b3cnewswire
June 20, 2018
SOTIO, a biotechnology company owned by the PPF Group, presented results from its Phase II clinical trials evaluating DCVAC, an active cellular immunotherapy product,
SOTIO Starts Phase I/II Trial of DCVAC in Combination with ONCOS-102: The Targovax Adenovirus Based Immunotherapy b3cnewswire.
June 04, 2018
SOTIO, a biotechnology company owned by the PPF Group, announces today that the first patient was enrolled to the SP015 clinical trial of a combination of DCVAC/PCa
Phase II Clinical Trials of DCVAC Show Significant Benefit for Patients with Ovarian and Lung Cancer b3cnewswire.
June 04, 2018
SOTIO, a biotechnology company owned by the PPF Group, presented results from its Phase II clinical trials evaluating DCVAC